Hanna John Walter JR sold $116K of CDNA

Hanna John Walter JR (President and CEO) sold 4,835 shares of CareDx, Inc. (CDNA) at $24.00 ($0.12M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jun 8, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The disclosure adds a fresh datapoint on insider liquidity activity; because it is under a pre-arranged 10b5-1 plan, it is less likely to signal deteriorating fundamentals.

02

Market read

Insider selling is disclosed, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

Traders may want to compare with prior insider sale/buy patterns and whether there are concurrent filings (e.g., other officers, 10b5-1 plan amendments) that could change interpretation.

Relevance 3/10Novelty 6/10Timing: Filed June 8, 2026 (transaction dated June 4, 2026)

Background

The article reports an SEC Form 4 insider transaction for CareDx, Inc. (CDNA) by its President and CEO.

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO Hanna John Walter Jr filed a Form 4 selling 4,835 shares (~$116k) via an open-market sale under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived unless accompanied by other news.

Evidence & confidence

The filing is a disclosed insider transaction (open-market sale) with an existing pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical catalyst.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical for liquidity/tax planning, so the market may overreact relative to the true information content.

Key entities

  • CareDx, Inc.

    Company whose shares were sold by the CEO under a 10b5-1 plan.

  • Hanna John Walter Jr

    President and CEO who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.